Clinical Research Directory

Inclusion Criteria: * Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study; * Male or female patient 18 to 75 years of age, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, and life expectancy ≥12 weeks; * Histologically or cytologically confirmed, locally advanced tumors, Priority will be given to subjects with HER2 positive solid tumo; * Malignant tumor that failed from standard treatment or had no standard treatment; * According to the RECIST 1.1 standard, patient with at least one evaluable lesion; * The main organs function well; * Male or female patient had no plans to become pregnant and voluntarily took effective contraceptive measures from agree with the study to at least 6 months after the last dose of study drug. Exclusion Criteria: * Concurrent secondary malignancy or other malignancy with no evidence of disease for more than 3 years; * History of uncontrolled intercurrent illness; * Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose; * Patients with known symptomatic brain metastases; * Receiving any other investigational agent within 4 weeks before first dose; * Patients with severe hypersensitivity after the use of monoclonal antibodies * History of interstitial lung disease or pneumonia; * Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.